文献速递慢性肾脏病水电解质与酸碱

拟钙剂治疗继发性甲状旁腺功能亢进的比较效果:系统综述与网状Meta分析

Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
PubMed 文献 · Am J Kidney Dis · 2020-05-28

该系统综述与网状Meta分析纳入36项随机对照试验共11247例成人慢性肾脏病患者,比较三种拟钙剂治疗继发性甲状旁腺功能亢进的效果。与安慰剂相比,拟钙剂达到目标PTH水平的几率更高;依特卡肽达到PTH目标的几率高于依沃卡肽和西那卡塞,但低钙血症风险更高。三种药物的副作用谱不同,无法确定单一优选药物。

要点

  • 拟钙剂达到目标PTH水平的几率高于安慰剂,证据确定性高或中等。
  • 依特卡肽达到PTH目标的几率高于依沃卡肽(OR 4.93)和西那卡塞(OR 2.78)。
  • 依特卡肽低钙血症风险高于西那卡塞和依沃卡肽,西那卡塞恶心风险高于安慰剂。

核心结论

  • 拟钙剂获益证据仅限于血清PTH这一替代终点的短期评估。
  • 依特卡肽降低PTH幅度最大,但三种拟钙剂副作用谱不同,无法确定单一优选药物。

研究设计与样本

  • 系统综述与网状Meta分析,纳入36项随机对照试验,共11247例成人慢性肾脏病患者。
  • 除4项试验外均涉及透析患者,中位随访26周(范围1周至21.2个月)。

主要发现

  • 与安慰剂相比,拟钙剂达到目标PTH水平的几率更高,证据确定性高或中等。
  • 依特卡肽达到PTH目标的几率高于依沃卡肽(OR 4.93;95% CI 1.33-18.2)和西那卡塞(OR 2.78;95% CI 1.19-6.67)。
  • 依特卡肽的低钙血症风险似乎高于西那卡塞和依沃卡肽。
  • 西那卡塞恶心风险高于安慰剂,依特卡肽恶心风险程度较轻。
  • 拟钙剂之间在死亡率、心血管终点或骨折风险方面的差异无法以足够确定性辨别。

关键数值与推荐

  • 主要结局为目标PTH水平下降的达成和低钙血症。
  • 其他结局包括恶心、呕吐、严重不良事件、全因死亡、心血管死亡、心力衰竭和骨折。

临床怎么用

  • 拟钙剂可用于短期降低PTH水平,但选择药物时需权衡低钙血症和恶心等副作用谱。
  • 依特卡肽降PTH作用较强但低钙血症风险较高,西那卡塞需关注恶心。
  • 长期硬终点获益证据不足,临床决策应结合患者个体情况。

局限性

  • 缺乏长期数据。
  • 终点定义存在异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Comparative benefits and harms of calcimimetic agents used for the treatment of secondary hyperparathyroidism have not been well characterized. We sought to compare the effectiveness of 3 calcimimetic agents using published data. STUDY DESIGN: Systematic review of randomized controlled trials and network meta-analysis. SETTING & STUDY POPULATION: Adults with chronic kidney disease enrolled in a clinical trial of a calcimetic agent. SEARCH STRATEGY & SOURCES: MEDLINE, EMBASE, CENTRAL (from February 7, 2013, to November 21, 2019), and a published meta-analysis. DATA EXTRACTION: Two reviewers independently extracted the study data, assessed risk of bias, and rated evidence certainty using Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria. ANALYTICAL APPROACH: Frequentist network meta-analysis was conducted. The primary review outcomes were achievement of a target reduction in serum parathyroid hormone (PTH) levels and hypocalcemia. Additional outcomes were nausea, vomiting, serious adverse events, all-cause mortality, cardiovascular mortality, heart failure, and fracture. RESULTS: 36 trials (11,247 participants) were included. All except 4 trials involved dialysis patients. Median follow-up was 26 weeks (range, 1 week to 21.2 months). Compared with placebo, calcimimetic agents had higher odds of achieving target PTH levels with high or moderate certainty. Etelcalcetide had the highest odds of achieving a PTH target compared with evocalcet (OR, 4.93; 95% CI, 1.33-18.2) and cinacalcet (OR, 2.78; 95% CI, 1.19-6.67). Etelcalcetide appeared to cause more hypocalcemia than cinacalcet and evocalcet. Cinacalcet and to a lesser extent etelcalcetide appeared to cause more nausea than placebo. Differences in risk for mortality, cardiovascular end points, or fractures across calcimimetic agents could not be discerned with sufficient certainty. LIMITATIONS: Lack of longer-term data; heterogeneous end point definitions. CONCLUSIONS: Evidence of the benefits of calcimimetic therapy is limited to short-term assessment of a putative surrogate outcome (serum PTH). Although etelcalcetide was associated with the largest reduction in PTH levels, side-effect profiles differed across the 3 calcimimetic agents, making it not possible to identify 1 preferred agent.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Palmer SC, Mavridis D, Johnson DW, et al. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis. Am J Kidney Dis. 2020. PMID: 32475604. doi:10.1053/j.ajkd.2020.02.439

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。